CD8A and neoplasm: Terranova-Barberio et al.51 have demonstrated that the immune characteristics of exhausted CD8+ T cells in peripheral blood and tumor samples may serve as potential biomarkers for predicting the efficacy of immune checkpoint inhibitors.